Mylan completes Meda acquisition

PITTSBURGH — Mylan on Thursday announced that it had completed the settlement of its recommended public offer to Meda’s shareholders to tender all shares of the company to Mylan. Shareholders with approximately 94% of Meda shares accepted the offer, and Mylan acquired each of them in accordance with the offer’s terms. 

 

“We are very pleased to have received the overwhelming shareholder support required to complete our acquisition of Meda,” Mylan chairman Robert Coury said. “Mylan continues to differentiate itself among the world's pharmaceutical companies in terms of our unique profile and growth trajectory. The addition of Meda will only further add to our existing leadership position within our space and continue to create significant value for our shareholders and other stakeholders.”

 

Meda is now a controlled subsidiary of Mylan. The company intends to start compulsory acquisition proceedings for the outstanding shares of the company in accordance with the Swedish Companies Act, and it has acted to have the Meda shares delisted from the Nasdaq Stockholm.